Glaucoma Therapeutics Market to Reach US$ 10,091.0 Mn by 2026, Increasing Prevalence of Glaucoma to Provide Impetus, says Fortune Business Insights
Key companies covered in the Glaucoma Therapeutics Market Research report include Merck & Co., Inc., Novartis AG, Allergan plc, Bausch & Lomb Incorporated, Teva Pharmaceutical Industry, Aerie Pharmaceuticals Pfizer, Inc., and Inotek Pharmaceuticals.among others.
Pune, July 15, 2019 (GLOBE NEWSWIRE) -- The global Glaucoma Therapeutics Market is likely to increase in the coming years due to increasing prevalence of the disease. According to a report published by Fortune Business Insights titled, “Glaucoma Therapeutics Market Size, Share and Global Trend by Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs), By Disease Indication (Open Angle Glaucoma, Angle Closure Glaucoma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026,” the market was valued at US$ 6,273.5 Mn in 2018. Fortune Business Insights states that the market will be valued at US$ 10,091.0 Mn by the end of 2026, thereby exhibiting a CAGR of 6.1% in the forecast period.
|
|||||
Browse Complete Report Details with Table of Content and Figures:
https://www.fortunebusinessinsights.com/industry-reports/glaucoma-therapeutics-market-100312
The global Glaucoma Therapeutics Market is likely to expand in the coming years due to the remarkable increase in glaucoma cases. Glaucoma has affected around 64 million people across the globe. Glaucoma is a disease that may affect the optic nerve and prevalence of any stage of glaucoma may result in partial or full blindness. The severity of glaucoma has led to an increased awareness among end users about ways to manage glaucoma and people have realized the importance of detecting and treating this disease at an early stage. The prevalence of glaucoma is inclined towards geriatric population and the increasing geriatric population across the world, is likely to have a positive impact on the global market. Furthermore, improved diagnostic tools for treatment of glaucoma are likely to favor the growth of the global Glaucoma Therapeutics Market in the forthcoming years.
Prostaglandin Analogues to be the Most Widely Used Product Type
Among all drug types, prostaglandin analogues are likely to emerge as the most widely used product type. Prostaglandin analogues are mostly recommended for the first line therapy for glaucoma, owing to their high efficacy and clinical success in glaucoma therapeutics. Prostaglandin analogues accounted for almost 40.8% of the global market share in 2018 and this share is likely to increase in the coming years. Furthermore, rising uptake of prostaglandin analogues is likely to favor the growth of the global Glaucoma Therapeutics Market.
Increasing Prevalence of Glaucoma - A Major Driver for the Market in Asia Pacific
The global Glaucoma Therapeutics Market is dominated by North America. Improved healthcare infrastructure and efficient treatment options have favored the growth of the regional market. The Glaucoma Therapeutics Market in North America was valued at US$ 2,405.9 Mn in 2018 and it is likely to increase further in the coming years. The Glaucoma Therapeutics Market in Asia Pacific is likely to exhibit the highest CAGR in the forecast period. The fast-paced growth in Asia Pacific can be accounted to increasing cases of glaucoma in the region. Furthermore, avtive government participation and contribution from private organizations towards awareness and prevention of glaucoma are likely to augment the growth of the global Glaucoma Therapeutics Market and will continue to boost the market in the forthcoming years.
Some of the leading companies that are operating in the global Glaucoma Therapeutics Market are Merck & Co., Inc., Novartis AG, Allergan plc, Bausch & Lomb Incorporated, Teva Pharmaceutical Industry, Aerie Pharmaceuticals Pfizer, Inc., and Inotek Pharmaceuticals.
Key companies covered in the report
- Merck & Co., Inc.
- Novartis AG
- Allergan plc
- Bausch & Lomb Incorporated
- Teva Pharmaceutical Industry
- Aerie Pharmaceuticals
- Pfizer, Inc.
- Inotek Pharmaceuticals
Speak to Analyst https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/glaucoma-therapeutics-market-100312
Table of Content:
-
Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Market Drivers
-
Key Insights
- Prevalence of Glaucoma by major countries
- Recent industry developments such as partnerships, mergers & acquisitions
- Pipeline analysis
- Reimbursement scenario by key countries
- Regulatory scenario for key countries
-
Global Glaucoma Therapeutics Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Disease Indication
- Open Angle Glaucoma
- Angle Closure Glaucoma
- Others
- Market Analysis, Insights and Forecast – By Drug Class
- Bets Blockers
- Prostaglandin Amalogues
- Latanoprost
- Bimatoprost
- Travoprost
- Others
- Alpha Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- Others
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Competitive Analysis
- Strategic Recommendations
Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/glaucoma-therapeutics-market-100312
Browse Related Reports:
-
Breast Cancer Therapeutics Market Size, Share and Global Trend by Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Cancer Type (Hormone Receptor, HER2+), and Geography Forecast till 2026
-
Retinal Disease Therapeutics Market Size, Share and Global Trend by Disease Indication (Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Retinal Vein Occlusion), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2026
-
Lung Cancer Therapeutics Market Size, Share and Global Trend by Therapy (Targeted, Therapy, Immunotherapy, Chemotherapy), By Cancer Type (Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026
- Immunology Market Size, Share and Global Trend By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressants, Polyclonal antibody (pAb) ), By Disease Indication ( Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection ), By Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Geography Forecast till 2025
About us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US :+1-424-253-0390
UK :+44-2071-939123
APAC :+91-744-740-1245
Email: sales@fortunebusinessinsights.com
Website: https://www.fortunebusinessinsights.com
Attachment
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
